PMID- 21505396
OWN - NLM
STAT- MEDLINE
DCOM- 20110708
LR  - 20151119
IS  - 0392-0488 (Print)
IS  - 0392-0488 (Linking)
VI  - 146
IP  - 2
DP  - 2011 Apr
TI  - Dendritic cells and cutaneous T-cell lymphomas.
PG  - 103-13
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that help orchestrate 
      the innate and adaptive immune systems to induce tolerance and immunity. They are 
      diversified in their phenotypes, stages of maturation, degrees of activation, and 
      functions. Several subtypes of DCs exist among human lymphoid tissues, 
      non-lymphoid tissues, and in peripheral blood. In the skin, three types of DCs 
      are described: Langerhans cells (LCs), dermal dendritic cells (DDCs), and 
      plasmacytoid dendritic cells (pDCs). In the peripheral blood, myeloid dendritic 
      cells (mDCs) and plasmacytoid dendritic cells are well described. Dysfunctional 
      DCs are found in many autoimmune disorders, allergies, and cancers. In this 
      paper, we focus on DCs as related to cutaneous T cell lymphomas (CTCLs). Abnormal 
      DC number and defective DC function are found in the blood of patients with 
      advanced stage Sezary syndrome (SS), a leukemic variant of CTCLs. Extracorporeal 
      photopheresis (ECP), an effective therapy for erythrodermic CTCLs, is thought to 
      work by inducing apoptosis of tumor cells and monocytes-derived DCs. DC 
      vaccination has been carried out successfully in some patients with CTCLs when 
      combined with immune modifiers like toll like receptor agonists, which may 
      enhance the function of DCs. However, DCs may perform a dual role in the 
      pathogenesis of CTCLs. Immature DCs (langerhans cells) could promote the survival 
      of malignant T cells. Further understanding of DCs and their role in CTCLs can 
      help us to uncover the pathogenesis of this disease and to further explore the 
      therapeutic uses of DCs.
FAU - Ni, X
AU  - Ni X
AD  - Department of Dermatology, University of Texas-MD Anderson Cancer Center, 
      Houston, TX, USA. xiaoni@mdanderson.org
FAU - Duvic, M
AU  - Duvic M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - G Ital Dermatol Venereol
JT  - Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa 
      italiana di dermatologia e sifilografia
JID - 8102852
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Biomarkers, Tumor/blood
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Langerhans Cells/immunology
MH  - Lymphoma, T-Cell, Cutaneous/immunology/pathology/prevention & control/*therapy
MH  - Mycosis Fungoides/therapy
MH  - *Photopheresis
MH  - Sezary Syndrome/therapy
MH  - Skin Neoplasms/immunology/pathology/prevention & control/*therapy
MH  - Treatment Outcome
EDAT- 2011/04/21 06:00
MHDA- 2011/07/09 06:00
CRDT- 2011/04/21 06:00
PHST- 2011/04/21 06:00 [entrez]
PHST- 2011/04/21 06:00 [pubmed]
PHST- 2011/07/09 06:00 [medline]
AID - R23114202 [pii]
PST - ppublish
SO  - G Ital Dermatol Venereol. 2011 Apr;146(2):103-13.